Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow mesenchymal stem cell infusion for traumatic spinal cord injury
jRCT2053210130Recruiting
- Sponsor
- Nipro Corporation
- Start
- May 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous bone marrow derived mesenchymal stromal cells in spinal cord injury (SCI) (2 cohorts), sponsored by Nipro Corporation. Primary endpoints: Primary endpoint - Cohort 1 and Primary endpoint - Cohort 2. Started May 2019; status: recruiting.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on jRCT2053210130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053210130.